Effects of co-administration of methanol leaf extract of *Catharanthus roseus* on the hypoglycemic activity of metformin and glibenclamide in rats

Ohadoma SC*, Michael HU

Department of Pharmacology and Toxicology, Madonna University, Elele Rivers State, Nigeria

**ARTICLE INFO**

Article history:
Received 22 February 2011
Received in revised form 10 April 2011
Accepted 15 May 2011
Available online 20 June 2011

**Keywords:**
*Catharanthus roseus*
Hypoglycemic activity
Metformin
Glibenclamide
Co-administration

**ABSTRACT**

**Objective:** To investigate the interacting effects of co-administration of methanol leaf extract of *Catharanthus roseus* (*C. roseus*) on the hypoglycemic activity of metformin as well as glibenclamide using experimental rats. **Methods:** Phytochemical analysis as well as acute toxicity and lethality (LD₅₀) test were carried out on its methanol leaf extract. The alloxan model for experimental induction of diabetes in rats was employed. Six groups comprising five rats each were used. Groups I, II and IV received 250 mg/kg of extract, 100 mg/kg of metformin and 1 mg/kg of glibenclamide respectively, while V and VI were administered metformin–extract and glibenclamide–extract combinations respectively at doses as above. Group I served as negative control and received only distilled water. All administration was done once daily for seven days. Fasting blood glucose was determined at 2, 12, 24, 72 and 168 h using a glucometer. One-way ANOVA with post-hoc tests was used to assess for significant difference due to administration of drug alone and with co-administration of drug and extract. **Results:** The LD₅₀ was 2121.32 mg/kg. The phytochemical studies indicated the presence of saponins, tannins, alkaloids, phlobatannins, flavonoids, triterpenoids, reducing sugars, anthraquinones and glycosides. All medicaments significantly reduced blood glucose levels when compared with control alone (*P*<0.05) with the highest percentage reduction in blood glucose (64.86%) exhibited by metformin–extract combination. **Conclusions:** The leaf extract of *C. roseus* significantly increases the hypoglycemic effect of metformin.

**1. Introduction**

The concomitant use of herbs and drugs is a growing trend especially in the elderly and management of chronic ailments[1]. Most of the chronic diseases are difficult to treat successfully with orthodox drugs[2,3]. Diabetes mellitus is one of these chronic ailments which has been acclaimed to be managed by traditional healer with over 400 plants reported to have anti-diabetic properties including *Vernonia amygdalina*[3], *Grononema latifolium*, *Catharanthus roseus* (*C. roseus*)[4,5]. These plant extracts are sometimes prepared as polyherbal mixtures[6]. The objective of this study is to investigate the scientific basis for the folkloric use of *C. roseus* in the treatment of diabetes by traditional healers whose patients also take prescription oral hypoglycemic drugs. The English names of *C. roseus* include: cape periwinkle, rose periwinkle and “Old–maid”[5]. The use of *C. roseus* in cancer chemotherapy is perhaps, the most popular of all its uses[7]. In Congo, the stem and root of *C. roseus* are used against diarrhea while in Brazil, an infusion of the leaf is used against internal bleeding and scurvy, as mouthwash against toothache, for cleansing and healing of chronic wounds[8,9]. The fresh juice from the flowers of *C. roseus* has been reported to exert antimicrobial effect[10]. *C. roseus* has been shown to contain various constituents which are implicated for its numerous pharmacological activities. Four indole alkaloids found to inhibit cell growth have been discovered namely vincristine, vinleurosin, vinblastine and vinposidin[7].

**2. Materials and methods**

**2.1. Plant material**

Fresh stalks of *C. roseus* were collected from the botanical garden and environs of the University of calabar in the month of October 2009 and authenticated by Dr. Owolabi of the department of botany, university of calabar. The fresh leaves of *C. roseus* were plucked from the stem and
air—dried at room temperature (26 °C). The dried leaf was pulverized into powder using an electric blender. The powdered leaf (150 g) was extracted with methanol by cold maceration for 48 h[11], and filtered to obtain the methanol extract. Using a rotary evaporator at reduced pressure, the extract was concentrated and further dried in the oven, yielding a value of 11.37 g (7.58% w/w). The extract was subjected to phytochemical analysis using standard methods[11,12].

2.2. Animals

Fifteen (15) mice (18–32 g) and thirty five (35) albino rats of both sexes (150–220 g) bred in the Laboratory Animals facility of the Department of Pharmacology and Toxicology, Madonna University, Elele, were used in the studies. The animals were maintained under standard laboratory situations and had free access to standard pellets (vital feeds, plc, Nigeria) and clean water. Prior to experimental uses, the animals were transferred to work area and allowed for two weeks of acclimatization.

2.3. Acute toxicity and lethality (LD$_{50}$) test

The acute toxicity and lethality tests (LD$_{50}$) of the methanol extract (ME) was determined, in mice, adopting the method described by Lorke[13].

2.4. Alloxan–induced diabetes test

The fasting blood glucose (FBG) of the albino rats was determined before induction of diabetes. Animals model Type 1 diabetes was then induced in the overnight–fasted animals by a single i.p. injection of 110 mg/kg alloxan monohydrate using distilled water as vehicle[14]. The FBG was then determined 48 h later to ensure induction of diabetes. Animals with blood glucose level of > 150 mg/dL were considered diabetic[9].

2.5. Animal grouping and experimental protocol

The diabetic animals were assigned into six groups of 5 rats each according to similar weights.

Group I: Served as control group and was orally administered 0.2 mL of distilled water once daily.

Group II: Were treated orally with 250 mg/kg of extract daily for 7 days.

Group III: Were treated orally with metformin 100 mg/kg daily for 7 days.

Group IV: Treated orally with glibenclamide 1 mg/kg daily for 7 days.

Group V: Treated orally with 250 mg/kg metformin and 250 mg/kg extract for 7 days.

Group VI: Treated orally with 1 mg/kg glibenclamide and 250 mg/kg extract for 7 days.

2.6. Determination of blood glucose

Glucometer (prestige Smart systems) was used for the determination of the blood glucose levels of the rats. Blood samples were obtained from the cut tail–tip of conscious rat and the glucose test–strip soaked with the blood was allowed to dry for 60 s and then inserted to be read by the glucometer. Basal and 48 h post–induction blood glucose levels were recorded. Thereafter, the extract, drug or drug–extract combinations were administered daily for 7 d. Blood glucose concentrations were measured at 2 h, 12 h, 24 h, 72 h and 168 h.

2.7. Statistical analysis

Data were expressed as mean±standard error of mean (SEM). Statistical comparisons were performed by one–way ANOVA, followed by Tukey–Kramer multiple comparisons test and student–Newman–Keuls multiple comparisons test and the values were considered statistically significant when $P$ value is less than 0.05 ($P<0.05$).

3. Results

3.1. Phytochemical constituents

The phytochemical studies showed the presence of alkaloid, tannins, phlobatannin, flavonoids, terpenoids, glycoside, reducing sugar and saponins saponins and flavonoids were most abundant (Table 1).

<table>
<thead>
<tr>
<th>Phytochemical constituents</th>
<th>Extract (7.58% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saponins</td>
<td>+++</td>
</tr>
<tr>
<td>Alkaloids</td>
<td>++</td>
</tr>
<tr>
<td>Tannins</td>
<td>++</td>
</tr>
<tr>
<td>Phlobatannins</td>
<td>+</td>
</tr>
<tr>
<td>Flavonoids</td>
<td>+++</td>
</tr>
<tr>
<td>Triterpenoids</td>
<td>+</td>
</tr>
<tr>
<td>Reducing sugars</td>
<td>+</td>
</tr>
<tr>
<td>Anthraquinones</td>
<td>+</td>
</tr>
<tr>
<td>Glycosides</td>
<td>+</td>
</tr>
</tbody>
</table>

Value in parenthesis is the extractive yield. +++ = heavy presence; ++ = medium presence; + = slight presence.

3.2. Acute toxicity and lethal tests

The acute toxicity test (LD$_{50}$) of methanol extract was calculated to be 2 121.32 mg/kg.

3.3. Hypoglycemic activity

The blood sugar level of the extract and extract–drug combinations showed significant difference at 2 h ($P<0.05$ and $P<0.01$, respectively), when compared to the control. The standard drugs alone showed no significant difference ($P>0.05$). Glibenclamide however, started manifesting significant activity at 72 h ($P<0.05$). Greater significant difference was shown by metformin and metformin–extract combination ($P<0.01$). All treatment groups showed significant variations at 168 h when compared with control. Metformin–extract combination showed extremely significant difference ($P<0.01$) when compared with the administration of metformin alone. The highest percentage reduction in blood glucose was shown by metformin–extract combination at 72 h (64.86%). The control group did not show any significant reduction in the blood glucose level throughout the experimental period ($P>0.05$) (Table 2).
Table 2
Fasting plasma glucose levels of alloxan–induced diabetic rats at intervals during daily oral administration of methanol extract of *C. roseus* (mg/dL).

<table>
<thead>
<tr>
<th>Group</th>
<th>Medication</th>
<th>Pre–induction FBG</th>
<th>Post–induction FBG</th>
<th>Fasting plasma glucose during treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Distilled water (1 mL/kg)</td>
<td>47.50±2.99</td>
<td>31.60±3.77</td>
<td>412.20±47.91</td>
</tr>
<tr>
<td>II</td>
<td>Extract (250 mg/kg)</td>
<td>46.75±5.25</td>
<td>205.67±0.70</td>
<td>79.00±3.355*</td>
</tr>
<tr>
<td>III</td>
<td>Metformin (100 mg/kg)</td>
<td>44.70±4.42</td>
<td>360.40±59.06</td>
<td>224.00±81.78</td>
</tr>
<tr>
<td>IV</td>
<td>Glibenclamide (1 mg/kg)</td>
<td>42.75±3.92</td>
<td>306.80±56.18</td>
<td>248.00±44.31</td>
</tr>
<tr>
<td>V</td>
<td>Metformin+extract</td>
<td>59.50±9.91</td>
<td>265.60±52.31</td>
<td>135.40±25.98</td>
</tr>
<tr>
<td>VI</td>
<td>Glibenclamide+extract</td>
<td>48.00±3.18</td>
<td>336.00±88.81</td>
<td>182.40±64.48</td>
</tr>
</tbody>
</table>

*P<0.05; **P<0.01 significant level when compared with control. ΔP<0.01 when compared with standard drug i.e. metformin.

4. Discussion

The results obtained in this study showed that methanol extract of *C. roseus* possess hypoglycemic effect. The presence of flavonoids, alkaloids, tannins, quinolones, saponins, glycosides and reducing sugar corroborate previous studies which have shown that plant extract containing flavonoids, alkaloids and saponins do possess hypoglycemic activities[1]. Glibenclamide is known to lower glucose concentrations in the blood primarily by stimulating pancreatic beta cells in response to food and causes an increased sensitivity of body cells to endogenous insulin hence reducing insulin resistance. On the other hand, metformin stimulates tissue uptake of glucose and increase insulin receptor binding[15–18]. The extract of *C. roseus* can be said to act in similar fashion to glibenclamide, but enhanced response to glucose by pronounced than metformin and glibenclamide. In addition to the pharmacodynamic factor (mechanisms of action of the herbal extract[17], the blood glucose lowering effect of *C. roseus* extract was more pronounced than metformin and glibenclamide. In addition to the pharmacodynamic factor (mechanisms of action of herb and drugs), pharmacokinetic tendencies of interaction such as enzyme inhibition may have played a role hence the delay in the appearance of significant difference between metformin–extract combination and metformin monotherapy until the 7th day[19]. Pharmacokinetic factors as alteration of absorption due to binding that has been reported with co-administration of some herbs[20], did not result in significant changes in hypoglycemic activity of the drugs. In conclusion, the leaf extract of *C. roseus* and metformin in alloxan–induced diabetic rats was synergistic whereas there was no observed interaction with glibenclamide. This gives credence to the folkloric use of *C. roseus* for the regulation of blood sugar.

Conflict of interest statement

We declare that we have no conflict of interest.

References